Prostamax

Mechanism of Action

Prostamax's proposed mechanism is the Khavinson short-peptide framework applied to prostate tissue: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation producing prostate-favourable transcriptional shifts.

Step 1 - Tissue distribution. At ~487.5 daltons (H-Lys-Glu-Asp-Pro-OH, molecular formula C20H33N5O9), Prostamax is small and moderately polar. Khavinson-group tritiated-peptide biodistribution work is described in the Russian-language bioregulator literature as showing uptake across multiple tissues, but it is not backed by a PubMed-indexed study we can verify. The prostate is anatomically divided into peripheral, central, and transition zones with different epithelial and stromal characteristics. Whether Prostamax reaches each zone's cells at functionally meaningful concentrations has not been established.

Step 2 - Prostate cell targeting. The framework-level claim is zone-selective or cell-type-selective prostate uptake. No direct experimental validation exists. Prostate tissue has a specific blood-prostate barrier and drug penetration patterns (relevant for antibiotic selection in prostatitis); whether KEDP penetrates this barrier efficiently is unknown.

Step 3 - Chromatin modulation of prostate programmes. Russian-language in vitro reports describe modulation of prostatic epithelial cell proliferation, reduced apoptosis markers under stress, and changes in androgen receptor signalling markers in cultured prostate cells; these are not PubMed-indexed or independently replicated. The proposed mechanism is preferential activation of prostatic homeostatic transcription programmes. Modern prostate biology methodology - single-cell transcriptomics on prostate organoids, ChIP-seq in prostate epithelial cells, CRISPR-based target validation - has not been applied to Prostamax.

Alternative conservative framing

A parsimonious interpretation treats Prostamax as an amino-acid source delivering lysine, glutamate, aspartate, and proline. Biological effects could reflect: (a) substrate delivery for prostatic protein synthesis, (b) proline-mediated collagen synthesis in prostate stroma, (c) glutamate/aspartate TCA cycle anaplerosis, or (d) non-specific nutritional support. Under this framing, equivalent amino-acid delivery by any means would produce similar effects.

Comparison to evidence-graded BPH mechanisms

• Alpha-1 adrenoceptor antagonists (tamsulosin, alfuzosin, silodosin) - block smooth muscle contraction in prostatic stroma and bladder neck, producing measurable urinary flow improvement. Receptor pharmacology mapped, decades of RCT data.
• 5-alpha reductase inhibitors (finasteride, dutasteride) - block conversion of testosterone to DHT, reducing prostate size over months. Androgen pathway understood, long-term RCT data available.
• PDE5 inhibitors (tadalafil 5 mg daily) - improve LUTS via NO/cGMP pathway, particularly useful when BPH and erectile dysfunction overlap. Mechanism characterised.
• Anticholinergics and beta-3 agonists - reduce detrusor overactivity in overactive bladder component of LUTS.
• Saw palmetto - proposed 5-alpha reductase inhibition plus anti-inflammatory effects. Clinical trials heterogeneous, with some showing benefit and others (STEP trial) showing no effect above placebo.
• Pygeum africanum - anti-inflammatory and growth-modulating effects on prostate. Modest evidence base.

Prostamax sits at a different level of mechanistic specification - framework-level hypothesis rather than measured pharmacology of defined targets.

Comparison to Prostatilen/Vitaprost

The parent polypeptide extract has modestly more clinical evidence - Russian-language reports in BPH, chronic prostatitis, and male infertility associated with chronic prostatitis describe improvements in IPSS scores, prostate-specific inflammation markers, and ejaculate quality, though none is PubMed-indexed or independently verifiable. Whether the synthetic KEDP reproduces the extract's effects has not been systematically tested. It is an open question whether the active component of the extract is KEDP, a different peptide, or a mixture of factors.

Receptor pharmacology

No GPCR, nuclear receptor, or defined enzyme target identified for Prostamax. It does not bind androgen receptor, alpha-adrenoceptors, or PDE5. It does not inhibit 5-alpha reductase. It does not directly affect inflammatory pathways (COX, LOX, NF-B) at characterised concentrations. The absence of a defined pharmacological target is characteristic of the Khavinson bioregulator class.

Relation to other male-health compounds

Among peptides relevant to male health, Semax and Selank have better-characterised neurological mechanisms and more published literature. BPC-157 has better-characterised tissue regeneration data. Among non-peptide prostate supplements, saw palmetto, beta-sitosterol, Pygeum, and rye pollen extracts all have more clinical data than Prostamax. Among prescription prostate medications, alpha-blockers, 5-alpha reductase inhibitors, and PDE5 inhibitors sit in a fundamentally different evidence tier.

Prostamax is a short synthetic peptide developed in Russia by Vladimir Khavinson and collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "prostate bioregulator" intended to support prostatic epithelium and stromal function in age-related benign prostatic hyperplasia (BPH), chronic prostatitis, and post-surgical prostate recovery. It is usually described in Khavinson-family publications as the tetrapeptide Lys-Glu-Asp-Pro (KEDP), sometimes rendered H-Lys-Glu-Asp-Pro-OH or K-E-D-P. Prostamax is the synthetic defined-sequence counterpart to Prostatilen (sometimes marketed as Vitaprost), a polypeptide extract prepared from bovine prostate tissue that has been used clinically in Russia since the 1980s and remains a registered pharmaceutical in the Russian Federation for BPH and chronic prostatitis. Prostamax sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Bronchogen, Cardiogen, Cartalax, Chonluten, Ovagen, and Testagen within the Khavinson short-peptide bioregulator family.

Outside Russia, Prostamax is not a registered pharmaceutical, not FDA- or EMA-reviewed, not listed in WADA categories, and does not appear in AUA, EAU, or NICE guidelines for BPH or chronic prostatitis management. Critically, no PubMed-indexed clinical trial supports Prostamax's prostate or BPH claims. The evidence attributed to it in vendor and community write-ups traces to Russian-language reports that are not Western-indexed, not placebo-controlled, and not independently verifiable - earlier drafts of this page cited specific author-year studies as support, but on checking, those citations pointed to unrelated papers and have been removed. The parent polypeptide extract (Prostatilen/Vitaprost) has a modestly larger clinical footprint than the synthetic tetrapeptide, with Russian-language reports describing benefit in chronic pelvic pain syndrome and BPH symptom scores; those reports fall short of modern AUA/EAU evidence standards, and we cite no PubMed-indexed trial as support because none exists. The synthetic Prostamax tetrapeptide evidence base is smaller still: Khavinson-group in vitro work, small rodent experiments, and uncontrolled observational series, reported in Russian-language literature without independent replication.

The central claim for Prostamax is the standard Khavinson short-peptide model applied to prostate tissue: passive membrane permeation into prostatic epithelial and stromal cells, nuclear import, and sequence-selective chromatin modulation producing preferential upregulation of prostatic homeostatic programmes while downregulating inflammatory and hyperproliferative patterns. The tissue-specific targeting claim - that KEDP selectively supports prostate rather than other reproductive or visceral tissue - is asserted within the Khavinson framework but not validated by modern biodistribution, structural biology, or prostate-specific transcriptomics.

BodyHackGuide covers Prostamax because it is sold online in post-Soviet supplement channels (typically 20 mg oral capsules or rectal suppositories) and appears in longevity and male-health discussions as a prostate-support bioregulator. We describe what is known, what is claimed, and what is missing - and we steer readers seeking evidence-graded prostate care toward interventions with substantial replication: PSA screening appropriate for age and risk, evaluation of lower urinary tract symptoms (LUTS) with IPSS scoring and urological workup, evidence-based pharmacotherapy for BPH (alpha-blockers like tamsulosin, 5-alpha reductase inhibitors like finasteride or dutasteride, phosphodiesterase-5 inhibitors like tadalafil for LUTS/ED overlap), evidence-based chronic prostatitis management, proven supplements (saw palmetto with mixed but some evidence, Pygeum, beta-sitosterol), surgical or minimally invasive procedures where indicated (TURP, Rezum, UroLift, HoLEP), and definitive management of prostate cancer where diagnosed. Prostamax is a plausible hypothesis. It is not, in 2026, an evidence-graded prostate therapy.

IUPAC Name

L-Lysyl-L-glutamyl-L-aspartyl-L-proline

CAS Number

Not yet available

Molecular Formula

Lys-Glu-Asp-Pro

Molecular Mass

487.51 g/mol

Lys-Glu-Asp-Pro (KEDP)

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Interaction Matrix

Get Prostamax Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Sign in to set alerts

Related Compounds

View All

Data Completeness

88%

Research Credibility